The MARINA Trial's Long-Term Safety Open-Label Extension is Shown by Antisense Oligonucleotide AOC 1001.

Published Date: 19 Oct 2023

Myotonic dystrophy type 1 measures of myotonia, strength, function, and patient reported outcome all showed consistent direction improvements with AOC 1001.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

2.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

3.

Early detection of breast cancer may be possible with AI-based mammography microcalcification detection and classification.

4.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

5.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot